Anti-PD-L1 antibody [28-8] (ab205921)

ab205921 has been referenced in 69 publications.

• Le Flahec G  et al. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Hum Pathol 72:135-143 (2018). IHC-P ; Human . PubMed: 29208565
• Sato K  et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115:71-74 (2018). PubMed: 29290265
• Nakagomi T  et al. New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. Oncotarget 9:10635-10649 (2018). PubMed: 29535832
• Sasaki K  et al. Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus: A case report. Mol Clin Oncol 8:533-538 (2018). PubMed: 29541462
• Tang Y  et al. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers. Oncol Lett 15:4988-4996 (2018). PubMed: 29552135
• Wang W  et al. Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. Oncotarget 9:12164-12173 (2018). PubMed: 29552300
• Sun C  et al. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. Nat Commun 9:1241 (2018). PubMed: 29593314
• Liu B  et al. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes. PLoS One 13:e0194594 (2018). PubMed: 29617441
• Teixidó C  et al. PD-L1 expression testing in non-small cell lung cancer. Ther Adv Med Oncol 10:1758835918763493 (2018). PubMed: 29662547
• Klepsch V  et al. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nat Commun 9:1538 (2018). PubMed: 29670099
• Chang H  et al. Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization. J Gynecol Oncol 29:e27 (2018). IHC-P ; Human . PubMed: 29400020
• Huang X  et al. Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC). Int Immunopharmacol 59:127-133 (2018). IF . PubMed: 29653410
• Hellmann MD  et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4 (2018). IHC-P ; Human . PubMed: 29657128
• Hellmann MD  et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell 33:853-861.e4 (2018). PubMed: 29731394
• Tang YC  et al. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo. Int J Oncol 52:127-138 (2018). PubMed: 29115601
• Ancevski Hunter K  et al. PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10 (2018). PubMed: 29119407
• Amatatsu M  et al. Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. Cancer Sci 109:814-820 (2018). PubMed: 29345842
• Oya Y  et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget 8:103117-103128 (2017). IHC ; Human . PubMed: 29262550
• Yang L  et al. Posttranscriptional Control of PD-L1 Expression by 17ß-Estradiol via PI3K/Akt Signaling Pathway in ERa-Positive Cancer Cell Lines. Int J Gynecol Cancer 27:196-205 (2017). PubMed: 27870715
• Sato Y  et al. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma. Pathol Int N/A:N/A (2017). IHC-P, IF ; Human . PubMed: 28139862
• Remon J  et al. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. Lung Cancer 106:70-75 (2017). PubMed: 28285697
• Majzner RG  et al. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer 123:3807-3815 (2017). PubMed: 28608950
• Zhang M  et al. Prognostic significance of PD-L1 expression and18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. Oncotarget 8:51630-51640 (2017). IHC-P ; Human . PubMed: 28881674
• Fujimoto D  et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep 7:11373 (2017). IHC ; Human . PubMed: 28900290
• Kim KJ  et al. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget 8:58887-58902 (2017). IHC-P ; Human . PubMed: 28938605
• Scognamiglio T & Chen YT Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. Head Neck Pathol N/A:N/A (2017). PubMed: 28948509
• Miyazaki T  et al. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol N/A:N/A (2017). IHC ; Human . PubMed: 28447277
• Gambichler T  et al. Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. Cancer Immunol Immunother N/A:N/A (2017). PubMed: 28501937
• Zhu J  et al. Clinical Significance of Programmed Death Ligand-1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. PLoS One 12:e0170879 (2017). IHC-P ; Human . PubMed: 28125702
• Amaya CN  et al. Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies. Pathology 49:292-296 (2017). IHC-P ; Human . PubMed: 28238417
• Chen S  et al. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Int J Cancer 140:1384-1395 (2017). IHC-P ; Human . PubMed: 27925176
• Jiao S  et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res N/A:N/A (2017). PubMed: 28167507
• Badros A  et al. Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma. Blood N/A:N/A (2017). IHC ; Human . PubMed: 28461396
• Moon EK  et al. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Ann Am Thorac Soc N/A:N/A (2017). PubMed: 28613923
• Bolognesi MM  et al. Multiplex Staining by Sequential Immunostaining and Antibody Removal on Routine Tissue Sections. J Histochem Cytochem 65:431-444 (2017). PubMed: 28692376
• Tsuchihashi K  et al. Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mol Clin Oncol 6:665-668 (2017). IHC-P ; Human . PubMed: 28515919
• Nakamura S  et al. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. PLoS One 12:e0186192 (2017). IHC ; Human . PubMed: 29049375
• Huang Z  et al. Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer. J Cancer 8:3190-3197 (2017). IHC . PubMed: 29158791
• Miao S  et al. miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression. Oncotarget 8:62143-62153 (2017). PubMed: 28977933
• Zhu J  et al. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol 28:e77 (2017). PubMed: 29027395
• Zhang Y  et al. Genetic and immune features of resectable malignant brainstem gliomas. Oncotarget 8:82571-82582 (2017). PubMed: 29137285
• Rimm DL  et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol N/A:N/A (2017). IHC ; Human . PubMed: 28278348
• He Y  et al. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Med Sci Monit 23:1208-1216 (2017). IHC ; Human . PubMed: 28275222
• Lazzari C  et al. SECOND-LINE THERAPY OF SQUAMOUS NON-SMALL CELL LUNG CANCER: AN EVOLVING LANDSCAPE. Expert Rev Respir Med N/A:N/A (2017). PubMed: 28467720
• Pai SI & Faquin WC Programmed cell death ligand 1 as a biomarker in head and neck cancer. Cancer N/A:N/A (2017). PubMed: 28472542
• Ács B  et al. PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study. Breast 35:69-77 (2017). IHC ; Human . PubMed: 28651116
• Brunnström H  et al. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Mod Pathol N/A:N/A (2017). IHC ; Human . PubMed: 28664936
• Fan Y  et al. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther 9:6075-6082 (2016). IHC ; Human . PubMed: 27785054
• Jin Z & Yoon HH The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instabilityvs. PD-L1. J Gastrointest Oncol 7:771-788 (2016). IHC . PubMed: 27747091
• Connor AA  et al. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol N/A:N/A (2016). IHC-P ; Human . PubMed: 27768182
• Adam J  et al. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. Ann Pathol N/A:N/A (2016). PubMed: 26778219
• Lim SH  et al. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther N/A:N/A (2016). PubMed: 26800463
• Lee L  et al. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. J Clin Pharmacol 56:157-69 (2016). IHC ; Human . PubMed: 26183909
• Sun WY  et al. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med 14:173 (2016). IHC ; Human . PubMed: 27286842
• Califano R  et al. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. Curr Oncol Rep 18:59 (2016). PubMed: 27484062
• Hutarew G PD-L1 testing, fit for routine evaluation? From a patholo?gist's point of view. Memo 9:201-206 (2016). IHC ; Human . PubMed: 28058063
• Phillips T  et al. Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer. Appl Immunohistochem Mol Morphol N/A:N/A (2015). IHC ; Human . PubMed: 26317305
• Motzer RJ  et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430-7 (2015). Human . PubMed: 25452452
• D'Angelo SP  et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 46:357-65 (2015). IHC-P, IHC ; Human . PubMed: 25540867
• Weber JS  et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375-84 (2015). Human . PubMed: 25795410
• Robert C  et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-30 (2015). Human . PubMed: 25399552
• Larkin J  et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373:23-34 (2015). Human . PubMed: 26027431
• Postow MA  et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-17 (2015). Human . PubMed: 25891304
• Gibney GT  et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 21:712-20 (2015). Human . PubMed: 25524312
• Gettinger SN  et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 33:2004-12 (2015). Human . PubMed: 25897158
• Brahmer J  et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373:123-135 (2015). IHC-P, IHC ; Human . PubMed: 26028407
• Rizvi NA  et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257-65 (2015). Human . PubMed: 25704439
• Weber JS  et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31:4311-8 (2013). Human . PubMed: 24145345
• Wolchok JD  et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-33 (2013). Human . PubMed: 23724867